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OBJECTIVE: To compare the costs and effectiveness of
general (GA) versus regional (RA) versus combination
(general/epidural) (GEA) of anesthetic/analgesic techniques
in patients undergoing hip arthroplasty. 
METHOD: In a prospective cohort open label multicenter
study in three major general hospitals in Athens, all 210
patients undergoing hip arthroplasty during a period of
one calendar year ending December 25, 1998 were stud-
ied. Patients were eligible for all anesthesia techniques.
Doctors followed their current anesthesia/analgesia tech-
nique. Total costs included all pre-, intra-, and postopera-
tive direct medical costs (health system perspective). Re-
source use was recorded and per hospital unit prices were
transformed to US dollars. Effectiveness was measured by
classifying patients in four intervals of pain intensity along
a linear Visual Analogue Scale (0–30VAS “excellent” anal-
gesia, 31–50VAS “good” analgesia, 51–70VAS “bad” an-
algesia, and 71–100VAS “insufficient” analgesia). Sepa-
rate cost and effectiveness analyses were performed and a
stochastic cost-effectiveness analysis model is being used to
calculate incremental cost-effectiveness ratios. 
RESULTS: Significant total-costs differences exist amongst
anesthetic/analgesic techniques (p  0.001). GA presented
higher operative costs than RA, whereas GEA presented
the highest postoperative costs. GEA showed clinically and
statistically significant lower pain scores at recovery room
and during the 4 postoperative days (p  0.001). Prelimi-
nary results indicate that a moderate increase in costs
through applying continuous postoperative epidural anal-
gesia (CEPA) is associated with better pain relief indicated
by lower numbers of patients in “bad” and “insufficient”
analgesia levels. 
CONCLUSIONS: Despite a moderate postoperative cost
increase, epidural anesthesia/analgesia and GEA result in
clinically significant improvements in patients’ pain relief
during the study period. Postoperative pain management
practices are key factors influencing the direction and
magnitude of costs and effects of the various anesthesia/
analgesia techniques.
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OBJECTIVE: To compare the effectiveness of general
(GA) versus epidural (EA) versus spinal (SA) versus a
combination (GEA) anesthetic technique in terms of pain
relief for patients undergoing hip arthroplasty. 
METHOD: In a prospective cohort open label multi-
center study in three major general hospitals in Athens,
Greece, all 210 patients undergoing hip arthroplasty dur-
ing a period of one calendar year ending December 25,
1998 underwent face-to-face interviews after surgery and
for 4 consecutive postoperative days. A Visual Analogue
Scale (VAS) was used to measure intensity of pain on a
continuous scale with the ends marked as “no pain”
(0mm) and “worst pain ever” (100mm) twice daily. After
controlling for demographics and ASA status, the study
arms were compared on the basis of physician-suggested
clinically meaningful pain intervals of: 0–30VAS (excel-
lent analgesia), 31–50VAS (good analgesia), 51–70VAS
(bad analgesia) and 71–100VAS (insufficient analgesia).
Ordinary least square regressions were run with pain in-
tensity as dependent variable and clinical, organizational,
physician and patient characteristics as independent ones.
RESULTS: Immediately after surgery, EA and GEA present
statistically significant higher numbers of patients in the
0–30VAS interval than the rest two anesthesia techniques
(p 0.005). EA and GEA also show lower numbers of pa-
tients at the “bad” and “insufficient” analgesia intervals
at a statistically significant level during the study period,
except for the third postoperative day. In regression anal-
ysis, locus of postoperative pain management responsibil-
ity, analgesia technique, and hospital practice variations
significantly accounted for clinically meaningful differ-
ences in postoperative pain levels. 
CONCLUSIONS: Epidural and general/epidural anesthetic
techniques result in more patients with excellent analgesia
immediately after hip arthroplasty. The use of continuous
postoperative epidural analgesia (CEPA) technique to-
gether with assigning anesthesiologists responsibility for
post operative pain management result in better pain relief
during a period of 4 postoperative days.
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Although pain is the most common presenting complaint
in emergency rooms (ERs), few ERs have written policies
on pain management. The Canadian Association of Emer-
gency Physicians recommends that to achieve rapid and
safe analgesia, parenteral use of medications should be
restricted to the intravenous (IV) route. The analgesic ef-
ficacy of ketorolac after IV and IM administration has
not been investigated. Ibuprofen 800 mg has been dem-
onstrated to provide comparable analgesia to IM ketoro-
lac 30 mg. 
OBJECTIVE: To evaluate the analgesic efficacy and ther-
apeutic onset of analgesia of parenteral ketorolac and
oral ibuprofen. 
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METHODS: A randomized, prospective, parallel, dou-
ble-blind, double-dummy trial was conducted to deter-
mine the analgesic efficacy and time to onset of analgesia
following IV and IM administration of ketorolac (15 mg
and 30 mg), and oral ibuprofen 800 mg (N  100). Pain
intensity was evaluated using visual analog and verbal
rating scales. 
RESULTS: Patients who received ketorolac (30 mg IV)
showed a greater decrease in pain intensity compared with
patients in all other groups (p  0.005). Fifty percent pain
relief before the end of the study was achieved by 50% of
patients in one group only: ketorolac (30 mg IV). 
CONCLUSION: Ketorolac (30 mg IV) provided a greater
degree of pain relief and a quicker time to onset of analge-
sia than all other groups. There were no differences in an-
algesic efficacy between ketorolac (30 mg IM), ketorolac
(15 mg IM), ketorolac (15 mg IV) and ibuprofen 800 mg.
ECONOMIC AND OUTCOMES ISSUES OF 
WOMEN’S AND MEN’S HEALTH DISORDERS
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OBJECTIVE: The purpose of this study was to compare
the 5-year costs of using various sequences of contracep-
tive methods. 
METHOD: We constructed a series of 20 Markov mod-
els, each describing a different sequence of contraceptive
choices over a 5-year time horizon, including one or
more oral contraceptives (COC or POP), Depo Provera,
the Copper IUD (Multiload Cu375 or Nova T), Mirena
and male or female sterilization as a backup option. 
RESULTS: Contraceptive sequences incorporating Mirena
are substantially more effective than those with the stan-
dard copper IUD at little or no additional cost to the
healthcare payer over a 5-year period, whether Mirena is
used as a first-line or second-line contraceptive method.
The higher up-front acquisition cost of the device com-
pared with the standard copper IUD is compensated by its
greater effectiveness in reducing the incidence of costly un-
planned pregnancy. Contraceptive sequences with Mirena,
Depo Provera or the IUD first-line are more effective and
less costly than sequences beginning with oral contracep-
tives first-line. Compared with no contraceptive method,
Mirena has the potential to realise net savings to the
Health Funding Authority of about $2200 per woman
over a 5-year period through preventing costly unplanned
pregnancy. 
CONCLUSIONS: These findings support Mirena either as
first-line contraception for women who have completed
their families or as a second-line contraceptive method for
women for whom the IUD or oral contraception is inap-
propriate or who cannot tolerate other methods.
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OBJECTIVE: The purpose of this analysis was to deter-
mine the cost impact of obtaining emergency contracep-
tion directly from a pharmacist in Washington state. 
METHODS: Using a range of published rates of concep-
tion and emergency contraceptive effectiveness, the num-
ber of pregnancies prevented was estimated for 6267
women obtaining emergency contraception from a phar-
macist in Washington state from February 25, 1998 to
December 31, 1998. The direct costs of the prevented
pregnancies were estimated using published data updated
to 1998 dollars for private and public payers. Both an
averted-birth and a delayed-birth assumption were em-
ployed. Resulting costs were compared to the cost of the
emergency contraception to assess the cost impact. 
RESULTS: In the base case, emergency contraception
prevented 334 pregnancies. In the public payer, averted-
birth model, use of emergency contraception resulted in
$482,851 saved. The public payer, delayed-birth model
resulted in cost savings of $123,801. In the private payer,
averted-birth model, emergency contraception resulted in
cost savings of $1,511,382. The private payer, delayed-
birth model resulted in cost savings of $552,134. When
analyzing the best and worst case scenarios, savings from
use of emergency contraception ranged from $107,769
to $7,430,724. The broad range of cost savings is attrib-
utable to the heterogeneity of conception and effective-
ness rates assumed. 
CONCLUSION: Emergency contraception prevents many
unintended pregnancies. Under most assumptions, the di-
rect cost of emergency contraception is lower than the di-
rect cost of unintended pregnancies. Emergency contracep-
tion provided directly by pharmacists is a cost saving
method of preventing unintended pregnancies.
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Impairment of quality of life (QoL) of menopausal women
has often been demonstrated using condition-specific QoL
instruments. However, condition-specific QoL data are of
relatively limited usefulness in deciding whether treat-
ments of proven efficacy such as hormone replacement
